@article {d {\ textquoteright} Ancona1902259，作者= {d {\ textquoteright}安科纳，GR {\'一个} INNE和卡瓦纳，Joanne和罗哈斯，克里斯和Green，Linda和费尔南德斯，马里亚纳和Thomson，Louise和达里瓦尔，Jaideep和Nanzer，亚历山德拉M.杰克逊，戴维·肯特，布莱恩D.}，标题= {坚持吸入糖皮质激素及临床疗效在美泊利单抗治疗重症哮喘}，elocation-ID = {1902259}，年= {2020}，DOI = {10.1183 / 13993003.02259-2019}，出版商= {欧洲呼吸协会}188bet官网地址，抽象= {简介吸入皮质类固醇（ICS）实现在大多数哮喘患者的疾病控制，尽管遵守规定的ICS往往较差。患有严重哮喘嗜酸性（SEA）可能需要与口服皮质类固醇（OCS）和/或生物剂如美泊利单抗的治疗。它是未知的，如果ICS坚持改变，或者改成，生物治疗提供我们检查了OCS依赖SEA病人谁完成1年美泊利单抗治疗的依从ICS和临床疗效的临床反应。该ICS药品占有比例计算（MPR;处方/预计发行数量剂量ICS的数）为前一年和生物开始后的一年。良好的粘附性被定义为MPR \> 0.75，中间：0.74 {\ textendash} 0.51和差：\ <0.5。我们12个月生物疗法，包括OCS减少和年度恶化率（AER），通过坚持分层，ICS上mepolizumab.Results 109例患者的检查后开始结果美泊利单抗，91谁曾完成了12个月的治疗被列入最后的分析。虽然接收美泊利单抗，68 \％具有良好的粘附ICS，与具有ICS依从性差16（18 \％）。ICS队列内使用仍然（MPR 0.81 {\ textpm} 0.32）之前和在美泊利单抗类似（0.82 {\ textpm} 0.32; P = 0.78）。 Patients with good adherence had greater reductions in OCS dose (median percentage OCS reduction 100(IQR 74{\textendash}100) versus 60(IQR 27{\textendash}100);p=0.031) and exacerbations (AER change -2.1{\textpm}3.1 versus 0.3{\textpm}2.5;p=0.011) than those with poor adherence. Good ICS adherence predicted the likelihood of stopping maintenance OCS (adjusted OR 3.19;95\%CI 1.02{\textendash}9.94;p=0.045).Conclusion ICS non-adherence is common in SEA patients receiving mepolizumab, and is associated with a lesser reduction in OCS requirements and AER.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Ms. D{\textquoteright}Ancona reports personal fees from GSK, during the conduct of the study; grants and personal fees from Astra-Zeneca, personal fees from Napp Pharmaceuticals, personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Teva Pharmacueticals, outside the submitted work.Conflict of interest: Dr. Kavanagh has nothing to disclose.Conflict of interest: Ms. Roxas has nothing to disclose.Conflict of interest: Ms. Green has nothing to disclose.Conflict of interest: Ms. Fernandes has nothing to disclose.Conflict of interest: Ms. Thomson has nothing to disclose.Conflict of interest: Dr. Dhariwal has nothing to disclose.Conflict of interest: Dr. Nanzer has nothing to disclose.Conflict of interest: Dr. Jackson reports grants and personal fees from Astra-Zeneca, outside the submitted work.Conflict of interest: Dr. Kent reports personal fees from GSK, during the conduct of the study; personal fees from Astra-Zeneca, personal fees from Napp Pharmaceuticals, personal fees from Chiesi Pharmaceuticals, non-financial support from Boehringer-Ingelheim, non-financial support from Teva Pharmacueticals, outside the submitted work.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2020/02/14/13993003.02259-2019}, eprint = {//www.qdcxjkg.com/content/early/2020/02/14/13993003.02259-2019.full.pdf}, journal = {European Respiratory Journal} }